HAYA Therapeutics, SA, a company specializing in RNA-guided precision medicines focused on long non-coding RNAs (lncRNAs), has announced that its Co-Founders, Samir Ounzain and Daniel Blessing, have been awarded the inaugural Andreas & Thomas Struengmann Award.
Dr. Ounzain, CEO and Co-Founder of HAYA Therapeutics, expressed gratitude for the honor, emphasizing the award’s significance in the biotech and life sciences sectors.
The Andreas & Thomas Struengmann Award recognizes entrepreneurial vision and talent in the life sciences within the DACH region (Germany, Austria, Switzerland). It specifically acknowledges Drs. Ounzain and Blessing for their leadership in advancing RNA-based precision medicines targeting lncRNAs, particularly for heart disease and other chronic conditions. The award, including a €100,000 cash prize, was presented to them during the Festival of the Future at the Deutsches Museum in Munich on June 28, 2024.
Dr. Ounzain reiterated HAYA’s commitment to bringing innovative therapies to underserved patient populations, citing the upcoming clinical studies for their lead program, HTX-001.
The award committee, including biotechnology leaders such as Prof. Dr. Özlem Türeci and Prof. Dr. Helmut Schönenberger, recognized HAYA’s groundbreaking approach and potential impact on therapeutic development.
Dr. Blessing, CTO and Co-Founder, acknowledged the support of the award committee and highlighted the contributions of the entire HAYA team in advancing their platform for RNA therapeutics.
HAYA Therapeutics aims to revolutionize disease treatment by leveraging its platform to develop precision therapies targeting lncRNAs derived from the dark genome. Their lead candidate, HTX-001, is slated for clinical trials targeting heart-specific conditions.
Andreas and Thomas Struengmann expressed their congratulations and underscored the award’s role in validating HAYA’s innovative approach in the life sciences sector.
The Andreas & Thomas Struengmann Award, established in 2024, aims to foster innovation and leadership in the DACH life sciences sector, honoring exceptional achievements that advance the field.
About HAYA Therapeutics
HAYA Therapeutics is dedicated to developing programmable therapeutics targeting regulatory RNAs from the dark genome for diseases such as cardiovascular disease and cancer. Headquartered in Lausanne, Switzerland, with laboratory facilities in San Diego, HAYA is supported by a strong investor consortium and led by experts in RNA-targeted therapeutics.
HAYA’s mission is to identify breakthrough therapies that offer superior efficacy, safety, and accessibility compared to existing treatments.
